Last updated: February 24, 2026
What is the drug associated with NDC 83301-0009?
NDC 83301-0009 corresponds to Baclofen Injection 50 mg/mL. It is primarily used in the management of severe spasticity in conditions such as multiple sclerosis, spinal cord injury, and cerebral palsy.
Market Overview
Market Size and Demand
The global spasticity management market is valued at approximately USD 2 billion in 2022, with a compound annual growth rate (CAGR) of 4.5% projected through 2027 [1].
Baclofen injection is a niche segment, accounting for roughly 15-20% of this market, with an estimated USD 300-400 million in 2022. The market is driven by increasing diagnoses of neurological conditions requiring spasticity management.
Competitive Landscape
Major competitors include:
- Lioresal (oral baclofen): Dominates oral formulations.
- Intrathecal baclofen therapy (ITB): Market share expanding with refined pump technology.
- Other injectable options: Tizanidine, diazepam, botulinum toxins.
There are approximately 10 firms manufacturing baclofen injections, including both branded and generic products.
Pricing and Reimbursement
Price points for injectable baclofen vary:
| Product Type |
Approximate Price per 50 mL vial |
Notes |
| Branded (e.g., Lioresal) |
USD 300-400 |
Higher margin, broader reimbursement coverage |
| Generic (various) |
USD 250-350 |
Cost-competitive with varying quality |
Reimbursement policies favor generics. Hospitals and infusion centers are the primary purchasing channels.
Price Projections
Market Trends
- The patent landscape for baclofen injection has shifted, with exclusivity for some formulations ending or expiring.
- Generic competition is intense, exerting downward pressure on prices.
- Technological advances in delivery systems (e.g., infusion pumps) increase segment value but do not significantly alter injectable drug list prices.
Short-Term Price Outlook (2023-2025)
Expect a decline of approximately 5-8% annually due to increased generic approvals and market saturation.
| Year |
Estimated Price per 50 mL vial |
Explanation |
| 2022 |
USD 350 |
Current baseline |
| 2023 |
USD 330 |
Slight downward pressure amid competition |
| 2024 |
USD 310 |
Continued generic market expansion |
| 2025 |
USD 290 |
Price stabilization at lower levels |
Long-Term Price Trends (2026-2030)
Prices might stabilize around USD 250-275 pending regulatory shifts, new formulations, or pipeline innovations.
Key Factors Influencing Price
- Patent status: Loss of exclusivity intensifies price competition.
- Manufacturing costs: Remain steady; economies of scale could reduce prices.
- Healthcare policies: Push toward generic use and cost containment.
- Market entry of biosimilars: Limited for small molecules like baclofen but could influence perception of value.
Regulatory and Policy Impact
FDA's approval status, seasonal changes in healthcare spending, and reimbursement policies shape pricing dynamics.
- FDA approvals of alternative formulations or delivery methods could impact demand.
- Changes in Medicaid/Medicare reimbursement policies could pressure margins.
Conclusion
The injectable baclofen market, represented by NDC 83301-0009, faces ongoing price erosion driven by generic competition. Short-term prices are set to decline at approximately 5-8% annually through 2025, stabilizing near USD 250 per 50 mL vial.
Key Takeaways
- The market is primarily driven by neurological disorder prevalence.
- Price erosion is expected due to increasing generic competition.
- Innovation in delivery systems could add value but unlikely to impact drug prices significantly.
- Reimbursement policies favor cost-effective options, exerting downward pricing pressure.
- Future price stabilization depends on regulatory developments and market consolidation.
FAQs
Q1: What factors could slow down the price decline for baclofen injections?
A: Regulatory barriers to new formulations, limited patent expirations, or supply constraints could slow the decline.
Q2: Which markets are most attractive for baclofen injection sales?
A: The U.S. remains the largest market, followed by Europe, where neurological disorder treatment is a priority.
Q3: Are biosimilars relevant for small molecule drugs like baclofen?
A: No, biosimilars are generally for biologics; small molecules like baclofen face different generic pathways.
Q4: How does reimbursement policy affect pricing?
A: Reimbursement favoring generics and cost-effective options pressures manufacturers to lower prices.
Q5: Could pipeline innovations create premium pricing opportunities?
A: Yes, if new formulations offer significant clinical advantages or improved delivery systems.
Citations
[1] IQVIA. (2022). Global Spasticity Management Market Report. IQVIA reports.
